Oppenheimer & CO Inc Viracta Therapeutics, Inc. Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding VIRX
# of Institutions
37Shares Held
3.66MCall Options Held
1.8KPut Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.63MShares$48,7870.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA289KShares$8,6750.0% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$8,6570.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny286KShares$8,5910.0% of portfolio
-
Black Rock Inc. New York, NY273KShares$8,1980.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $1.13M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...